POTOMAC, MARYLAND – November 03, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for
POTOMAC, MARYLAND – October 22, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today
POTOMAC, MARYLAND – October 14, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for
POTOMAC, MARYLAND October 10, 2025 / IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease, today announced
IGC-1C Targets Tau Protein’s Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MARYLAND – October 7, 2025 – IGC Pharma, Inc. (“IGC
POTOMAC, MD, September 29, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an
POTOMAC, MARYLAND, September 24, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced preclinical findings on TGR-63, the Company’s investigational small-molecule candidate for Alzheimer’s disease. The data demonstrate that TGR-63
POTOMAC, MARYLAND, September 22, 2025 – IGC Pharma, Inc. (NYSE American: IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer’s disease, today announced it has reached a key enrollment
POTOMAC, MARYLAND, September 9, 2025 – IGC Pharma, Inc. (NYSE American: IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer’s disease, today announced that its Artificial Intelligence (AI) team
POTOMAC, MD, September 02, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in